NCT06161272View on ClinicalTrials.gov

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2023

Primary Completion Date

March 10, 2025

Study Completion Date

January 10, 2026

Conditions

Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal CarcinomaFallopian Tube Cancer

Interventions

DRUG

Fluzoparib

single

DRUG

Fluzoparib+Apatinib

combination

Trial Locations (1)

Unknown

Affiliated Tumor Hospital of Guangxi Medical University., Nanning

All Listed Sponsors

lead

Guangxi Medical University

OTHER

NCT06161272 - Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | Biotech Hunter | Biotech Hunter